版本:
中国

BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept

April 10 Oncomed Pharmaceuticals Inc

* Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept

* Oncomed - Bayer Pharma notified co of decision not to exercise option to license WNT pathway inhibitors vantictumab, ipafricept for strategic reasons

* Oncomed - Effective June 2017, co to retain worldwide development & commercialization rights to vantictumab, ipafricept, WNT pathway biologics

* Oncomed Pharmaceuticals Inc - small molecule program under companies' collaboration continues without change

* Oncomed - will be conducting internal portfolio review and prioritization to determine next steps for all programs, including vantictumab, ipafricept Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐